Moreso, FrancescCrespo, MartaRuiz, Juan CTorres, ArmandoGutierrez-Dalmau, AlexOsuna, AntonioPerelló, ManelPascual, JulioTorres, Irina BRedondo-Pachón, DoloresRodrigo, EmilioLopez-Hoyos, MarcosSeron, Daniel2023-01-252023-01-252017-10-24http://hdl.handle.net/10668/11613There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)enclinical research/practiceclinical trialkidney (allograft) function/dysfunctionkidney transplantation/nephrologypathology/histopathologyrejection: antibody-mediated (ABMR)AdultAllograftsChronic DiseaseDouble-Blind MethodFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHLA AntigensHumansImmunoglobulins, IntravenousImmunologic FactorsIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationMaleMiddle AgedPostoperative ComplicationsPrognosisProspective StudiesRisk FactorsRituximabTissue Donorsresearch article28949089open access10.1111/ajt.145201600-6143https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.14520